Bruker Showcases Extended Automation in Biophysics SLAS2026

BILLERICA, Massachusetts – February 9, 2026 – At SLAS2026 in Boston, Bruker Corporation (Nasdaq: BRKR) is showcasing new capabilities in automated biophysics, designed to increase throughput, improve reproducibility, and seamlessly integrate into modern automated labs. Bruker is exhibiting at Booths #1620.

Next Generation SPR and Biophysical Automation

At SLAS2026, Bruker introduces the SPR Pro8 Series, the next generation of its Surface Plasmon Resonance portfolio for biomolecular interaction analysis. Available with 24 or 32 measurement spots, the SPR Pro8 systems now offer multi-buffer capability with up to eight buffer conditions in a single automated run — a feature previously exclusive to the flagship Triceratops SPR #64. This enables efficient assay development and multi-condition screening without manual intervention.

Replacing the SPR-24 Pro and SPR-32 Pro platforms, the SPR Pro8 Series complements the high-end Triceratops SPR #64 — Bruker’s most powerful and flexible SPR system — by providing optimized throughput and reliability for automated laboratory environments. All Bruker SPR systems integrate seamlessly with Genedata Screener for central data management as well as automated and consistent QC and analysis across instruments.

Bruker’s SPR portfolio offers exceptional throughput and multiplexing capabilities with full flexibility to cover applications from assay development to automated screenings.

Bruker’s heliX^® systems will also be featured as part of its integrated biophysical portfolio. The heliX⁺ offers unique capabilities for complex interaction kinetics, including multispecific binders, ternary complexes, conformational changes. The heliX^cyto is the first biosensor able to perform single-cell Interaction Cytometry (scIC) on living single cells, making it an ideal complement to the high throughput Pro8 and Triceratops platforms.

timsTOF MALDI PharmaPulse^® Brings Mass Spectrometry to Million-Compound Screening in the Era of AI-Driven Drug Discovery

The timsTOF MALDI PharmaPulse^®, showcased at Bruker’s booth #1620, combines the full advantages of Bruker’s MALDI mass spectrometry with the latest timsTOF technology to enable fully automated, label-free high-throughput screening of millions of compounds. Seamlessly integrated with Genedata Screener for advanced data analysis and workflow automation, this powerful platform delivers unprecedented speed and specificity, enabling researchers to identify the most promising leads with maximum confidence using state-of-the-art mass spectrometry technology.

"These new features and capabilities further strengthen Bruker’s biophysical and screening portfolio," said Meike Hamester, PhD, Vice President Bruker Biosensors. "Across our SPR platforms and the timsTOF MALDI PharmaPulse^®, enhanced automation, high flexibility, and multiplexing enable our technologies to address virtually any throughput requirement — from early assay development to advanced, AI-driven screening workflows."

SLAS2026 Workshop

Bruker will host the workshop: "Tackling new challenges in automated biophysical characterization: from high throughput hit screening, to bioparticle characterization, to kinetics directly on cells", Monday, February 9, 2:00 pm EST. The session will highlight the combined strengths of the SPR Pro8 Series, Triceratops SPR #64 and the heliX^® systems across a range of mechanistic and throughput requirements.

Next-Generation Bioparticle Analysis and Lab Automation Solutions

Bruker will additionally launch a new label-free technology for bioparticle characterization and will showcase advanced lab automation and closed-loop AI & Robotics systems at SLAS2026. Read more in the corresponding press releases:

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker is enabling innovation and customer success in post-genomic life science molecular and cell biology, in disease biology and translational research, in specialty diagnostics, in applied and biopharma applications, as well as in industrial and cleantech research and QC, and in next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring. For more information, please visit www.bruker.com.